Niagen Bioscience, Inc. NAGE
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -1.17M | 963.00K | 6.32M | 4.13M | 4.58M |
| Total Depreciation and Amortization | 473.00K | 470.00K | 464.00K | 368.00K | 359.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.66M | 1.81M | -2.86M | -152.00K | 1.76M |
| Change in Net Operating Assets | 1.67M | -472.00K | -5.12M | -3.67M | -3.00M |
| Cash from Operations | 2.63M | 2.77M | -1.19M | 679.00K | 3.69M |
| Capital Expenditure | -52.00K | -89.00K | -61.00K | -101.00K | -24.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 0.00 | 0.00 | 5.80M | -- | -- |
| Other Investing Activities | 0.00 | -3.00K | -494.00K | -- | -- |
| Cash from Investing | -52.00K | -92.00K | 5.25M | -101.00K | -24.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -2.00K | -4.00K |
| Issuance of Common Stock | 196.00K | 278.00K | 111.00K | 228.00K | 152.00K |
| Repurchase of Common Stock | 0.00 | -2.77M | -2.35M | -251.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | -47.00K | -55.00K | 0.00 |
| Cash from Financing | 196.00K | -2.49M | -2.29M | -80.00K | 148.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.77M | 191.00K | 1.76M | 498.00K | 3.82M |